본문으로 바로가기 주메뉴 바로가기

사용자별 맞춤메뉴

자주찾는 메뉴

추가하기
닫기

연구성과

contents area

detail content area

Expression levels of FGFR3 as a prognostic marker for the progression of primary pT bladdercancer and its association with mutation status.
  • 작성일2018-02-14
  • 최종수정일2018-02-14
  • 담당부서연구기획과
  • 연락처043-719-8033
  • 2,384
ONCOLOGY LETTERS, 2017, 01, 3817─3824, DOI: https://doi.org/10.3892/ol.2017.6621

Expression levels of FGFR3 as a prognostic marker for the progression of primary pT bladdercancer and its association with mutation status.

Kim Wun-jae, Kang HW; Kim YH; Jeong P; Park C; Kim WT; Ryu DH; Cha E; Ha YS; Kim TH; Kwon TG; Moon SK; Choi YH; Yun SJ

Abstract

    In the present study, we used 195 prostate tissue samples obtained from patients with prostate cancer (PCa) and benign prostatic hyperplasia to evaluate the value of KIF11 as a cancer biomarker for PCa using real-time polymerase chain reaction.
    Our results suggest that KIF11 has potential value as a prognostic marker for PCa.
    Background
    KIF11 (kinesin family member 11), a molecular motor protein, is essential to mitosis and cell cycle progression. Inhibitors of KIF11 have been developed as chemotherapeutic agents for the treatment of various cancers. Regarding prostate cancer (PCa), clinical trials using KIF11 inhibitors for the treatment of castration-resistant PCa have been initiated. We hypothesized that a relationship might exist between KIF11 expression and PCa. To investigate the functional activities and clinical usefulness of KIF11 in PCa, we used quantitative real-time reverse tranase polymerase chain reaction to monitor the KIF11 expression patterns.
    Materials and Methods
    Tissue samples from 134 patients with PCa were analyzed using gene expression profiling and compared with tissues from 61 patients with benign prostatic hyperplasia. KIF11 expression was evaluated by real-time reverse tranase polymerase chain reaction and compared with indicators of tumor aggressiveness, such as prostate-specific antigen (PSA) levels, Gleason score (GS), and tumor stage (TNM stage).
    Results
    KIF11 mRNA expression in tissue was significantly greater in PCa patients with elevated serum PSA levels ( 10 ng/mL), GS 8 [58(43.3%)], T stage T3, or metastatic disease than in those with PSA levels < 10 ng/mL, GS of 7, or T2 stage. Additionally, the expression was remarkably greater in patients with a GS of 9 than in patients with a GS of 3þ4.
    Conclusion
    KIF11 expression might be indicative of PCa aggressiveness and could be useful as a prognostic marker for patients with PCa.



  • 본 연구는 질병관리본부 연구개발과제(과제번호 2017-보건의료생물자원종합관리) 연구비를 지원받아 수행되었습니다.
  • This research was supported by a fund(code 2017-보건의료생물자원종합관리) by Research of Korea Centers for Disease Control and Prevention.


본 공공저작물은 공공누리  출처표시+상업적이용금지+변경금지 조건에 따라 이용할 수 있습니다 본 공공저작물은 공공누리 "출처표시+상업적이용금지+변경금지" 조건에 따라 이용할 수 있습니다.
TOP